Table 1.
Patient and lesion characteristics
| Parameter | Number | % |
|---|---|---|
| Patient treated | ||
| Total | 37 | |
| V-MAT | 17 | 46 |
| Helical tomotherapy | 20 | 54 |
| Lesions treated | 38 | |
| V-MAT | 17 | 45 |
| helical tomotherapy | 21 | 55 |
| Male/female ratio | 27/10 | 73/27 |
| Primary tumor | ||
| NSCLC | 27 | 73 |
| SCLC | 10 | 27 |
| Adrenal metastasis appearance | ||
| Synchronous | 14 | 37 |
| Metachronous | 24 | 63 |
| Oligoprogressive | 17 | 45 |
| Oligorecurrent | 7 | 18 |
| Median time between diagnosis of primary | 14 months | |
| and adrenal metastasis | (0–108) | |
| Additional site of metastasis | ||
| Yes | 14 | 38 |
| One | 8 | |
| More than one | 6 | |
| No | 23 | 72 |
| Adrenal metastasis diagnosis | ||
| Biopsy | 0 | |
| PET | 29 | 76 |
| CT | 9 | 24 |
| Adrenal metastasis laterality | ||
| Left | 25 | 66 |
| Right | 13 | 34 |
| Bilateral | 1 |
CT, computed tomography; NSCLC, non-small-cell lung cancer; PET, positron emission tomography;SCLC, small-cell lung cancer;VMAT, volumetric modulated arc therapy;
NSCLC, non-small-cell lung cancer; PET, positron emission tomography;SCLC, small-cell lung cancer;VMAT, volumetric modulated arc therapy.